| 
 | Denosumab (n = 48) | Zoledronic acid (n = 56) | 
| Median age (years) | 65.3 (51~79) | 63.1 (55~78) | 
| Pathological method | 
 | 
 | 
| Radical prostatectomy | 10 | 13 | 
| Prostatic puncture | 36 | 41 | 
| Bone puncture | 2 | 2 | 
| Gleason score | 
 | 
 | 
| 6 | 4 | 6 | 
| 7 | 8 | 10 | 
| 8 | 8 | 10 | 
| 9 | 14 | 14 | 
| 10 | 14 | 16 | 
| Bone metastasis at first Diagnosis | 30 | 36 | 
| Hormone resistance | 18 | 21 | 
| Site of bone metastasis | 
 | 
 | 
| Quadrilateral bone | 12 | 13 | 
| Spine | 16 | 19 | 
| Multiple bone metastases | 20 | 24 | 
| Abnormal renal function | 5 | 6 | 
| Spinal cord compression | 5 | 5 | 
| Concomitant therapy | 
 | 
 | 
| Endocrine therapy | 42 | 50 | 
| Chemotherapy | 10 | 12 | 
| Bone operation | 3 | 2 | 
| Radiotherapy | 
 | 
 | 
| Bone metastasis | 15 | 17 | 
| Prostate | 18 | 23 | 
| PSA (ug/L) | 18 (6.7~55) | 16 (7~49) | 
| Basal bone pain (NRS score) | 
 | 
 | 
| ≤3 | 33 | 39 | 
| 4~6 | 10 | 7 | 
| 7~10 | 5 | 7 | 
| Median duration of medication (month) | 12 (8~24) | 13 (10~27) |